Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery

被引:3
|
作者
Choi, Soon Min [1 ]
Kim, Dong Gyu [2 ]
Lee, Ji-Eun [2 ]
Ho, Joon [2 ]
Kim, Jin Kyong [2 ]
Lee, Cho Rok [2 ]
Kang, Sang-Wook [2 ]
Lee, Jandee [2 ]
Jeong, Jong Ju [2 ]
Chung, Woong Youn [2 ]
Nam, Kee-Hyun [2 ]
机构
[1] Chung Ang Univ, Gwangmyeong Chung Ang Hosp, Dept Surg, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Dept Surg, Yonsei Canc Ctr,Coll Med, Seoul, South Korea
关键词
Thyroid lobectomy (TL); recurrence; prognosis; thyroid cancer; TERT PROMOTER MUTATIONS; LYMPH-NODE METASTASIS; COMPLETION THYROIDECTOMY; PROGNOSTIC-FACTORS; BRAF V600E; PAPILLARY; CARCINOMA; ASSOCIATION; RECURRENCE; SURVIVAL;
D O I
10.21037/gs-22-158
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) after thyroid lobectomy (TL). We evaluated proper surgical methods by analyzing oncologic outcomes of TL in patients with DTC whose risk had been upgraded after surgery. Methods: We retrospectively reviewed the medical records of 1,702 patients with DTC who underwent TL and ipsilateral central lymph node (LN) dissection between January 2006 and December 2011. The patients were classified into Group A ( n=1,159; low risk; <= 5 central LN metastases or the absence of pathologic microscopic capsular invasion) and Group B (n=543; upgraded intermediate risk after surgery; >5 central LN metastases or the presence of pathologic microscopic capsular invasion). We analyzed their clinicopathological characteristics and recurrence-free survival. Results: All 32 patients who experienced recurrence underwent CT. After the first operation, the duration until reoperation in Groups A and B were 8.00 +/- 2.74 ( range, 3.42-12.17) and 5.10 +/- 3.09 (range, 1.25-11.67) years, respectively. There was no significant difference in recurrence rates, disease-related mortality rates, or 10-year recurrence-free survival rates between the two groups. The mean follow-up durations in Groups A and B were 10.22 +/- 1.58 and 10.13 +/- 1.47 years, respectively. Univariate analysis showed that sex, age, tumor size, multifocality, extrathyroidal extension (ETE), and number of central LN metastases were not associated with recurrence after TL, although the rate of central LN metastases was. Multivariate analysis showed that sex, age, tumor size, multifocality, ETE, central LN metastases, and the number of central LN metastases were not associated with recurrence after TL, although multifocality was. Conclusions: TL with prophylactic central compartment neck dissection (CCND) is sufficient for patients with DTC whose risk is upgraded after surgery because they have a good prognosis at long-term follow-up. Larger-scale randomized clinical trials are required to confirm our findings.
引用
下载
收藏
页码:1451 / 1463
页数:13
相关论文
共 50 条
  • [21] Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors
    Lamartina, Livia
    Borget, Isabelle
    Mirghani, Haitham
    Al Ghuzlan, Abir
    Berdelou, Amandine
    Bidault, Francois
    Deandreis, Desiree
    Baudin, Eric
    Travagli, Jean-Paul
    Schlumberger, Martin
    Hartl, Dana M.
    Leboulleux, Sophie
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (03): : 1020 - 1031
  • [22] Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers
    Rajjoub, Samer R.
    Yan, Huan
    Calcatera, Natalie A.
    Kuchta, Kristine
    Wang, Chi-Hsiung E.
    Lutfi, Waseem
    Moo-Young, Tricia A.
    Winchester, David J.
    Prinz, Richard A.
    SURGERY, 2018, 163 (05) : 1134 - 1143
  • [23] Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers
    Chopra, Prakshi
    Kumar, Chitresh
    SURGERY, 2019, 165 (02) : 486 - 487
  • [24] Thyroid Lobectomy is Not Sufficient for T2 Papillary Thyroid Cancers
    Rajjoub, Samer R.
    Kuchta, Kristine
    Wang, Chihsiung E.
    Lutfi, Waseem
    Moo-Young, Tricia A.
    Winchester, David J.
    Prinz, Richard A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : E15 - E15
  • [25] Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option
    Jérôme Clerc
    Frederik A. Verburg
    Anca M. Avram
    Luca Giovanella
    Elif Hindié
    David Taïeb
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 918 - 925
  • [26] Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option
    Clerc, Jerome
    Verburg, Frederik A.
    Avram, Anca M.
    Giovanella, Luca
    Hindie, Elif
    Taieb, David
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 918 - 925
  • [27] Thyroid surgery for differentiated thyroid cancer — recent advances and future directions
    Tracy S. Wang
    Julie Ann Sosa
    Nature Reviews Endocrinology, 2018, 14 : 670 - 683
  • [28] Thyroid surgery for differentiated thyroid cancer - recent advances and future directions
    Wang, Tracy S.
    Sosa, Julie Ann
    NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (11) : 670 - 683
  • [29] Immune parameters in patients with differentiated thyroid cancer before and after the surgery
    Bubnova, LN
    Glazanova, TV
    Chernikov, RA
    GENES AND IMMUNITY, 2004, 5 : S54 - S54
  • [30] DIFFERENTIATED THYROID-CANCER - LOCAL RELAPSE AFTER LIMITED SURGERY
    HENRY, JF
    MARCHIONI, AM
    AUDIFFRET, J
    HANS, D
    BORSARELLI, J
    PRESSE MEDICALE, 1984, 13 (27): : 1671 - 1674